MSAC Ratified PICO Confirmation Application 1555 Endoscopic Sleeve Gastroplasty for Obesity Class I and II

The study compared the efficacy of endoscopic sleeve gastroplasty versus lifestyle interventions (behavioural therapy, diet and exercise) with or without pharmacotherapy in patients with class I and II obesity.


MSAC Ratified PICO Confirmation Application 1555 Endoscopic Sleeve Gastroplasty for Obesity Class I and II - cover page
Brand
MSAC
Category
Health Care
Document type
Other
Language
English
Pages
29
File format
PDF
File size
1.7 MB
Published
15 November, 2023
Updated
15 November, 2023
MD5 checksum
392B99AB771FE1DCEAB6AD2F34230532

About this manual

This Ratified PICO Confirmation from February 2019 outlines the Medical Services Advisory Committee (MSAC) assessment framework for Application 1555, which proposes endoscopic sleeve gastroplasty for patients aged 18 years or over with BMI 30.0–39.9 kg/m² who have major medical comorbidities and have failed first- and second-line treatments. The document defines the patient population, intervention (endoscopic sleeve gastroplasty plus lifestyle interventions), comparators (lifestyle interventions alone for BMI 30.0–34.9; sleeve gastrectomy or laparoscopic adjustable gastric banding plus lifestyle for BMI 35.0–39.9), and outcomes including safety, efficacy, healthcare resources, and cost-effectiveness.

The document provides background on obesity prevalence in Australia, noting 4.9 million Australians classified as obese (4.3 million in class I or II), common comorbidities (arthritis 27.7%, hypertension 24.5%, mental health problems 22.6%, diabetes 12.8%), and current chronic disease model of care. Treatment failure is defined as inability to achieve minimum 5% weight loss within 3 months. The rationale considers clinical need for durable weight loss beyond short-term lifestyle interventions.

What's inside

  • Component Description
  • Population
  • Obesity Definition and Measurement
  • Consequences of Obesity
  • Prevalence of Obesity in Australia
  • Current Care and Management
  • Rationale for Endoscopic Sleeve Gastroplasty

Frequently asked questions

What is the patient population for endoscopic sleeve gastroplasty in this assessment?

Patients aged 18 years or over with BMI 30.0–39.9 kg/m² who have one or more major medical comorbidities and have failed first- and second-line treatment options.

How is treatment failure defined in this application?

Treatment failure is defined as an inability to achieve a minimum of 5 per cent weight loss within 3 months.

Download PDF (1.7 MB)